Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia

• Status: Recruiting
• Trial end date: 2099-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Analysis of the efficacy and the compatibility of deep regional hyperthermia in combination with radiotherapy and chemoradiotherapy in bladder cancer

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Erlangen-Nürnberg Medical School
• Treatments: Fluorouracil

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Histologically confirmed bladder cancer

• M0

• ECOG-performance status ≤ 2

• Informed consent

Exclusion Criteria:

• Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy

• Cardiac Pacemaker

• Myocardial infarction within the past 12 months

• Congestive heart failure

• Complete bundle branch block

• New York Heart Association (NYHA) class III or IV heart disease

• Disease that would preclude TUR, chemoradiation or deep regional hyperthermia

• Metal implants (lenght > 2cm or dense clusters of marker clips in the pelvis)

• Active or therapy-resistent bladder infections

• Pre-existing or concommitant immunodeficiency Syndrom

• Pregnant or lactating women

• Patients not willing to use effective contraception during and up to 6 months after therapy